ERBB2 and breast carcinoma: Among four major adjuvant trials more than 13.000 women with HER2-positive early breast cancer were enrolled.5 All four studies report on the extension of time to disease recurrence and the overall survival if one year of the treatment with trastuzumab is added to the standard chemotherapy (CT).3,6,7 As an adjuvant treatment of breast cancer in these studies patients firstly received anthracyclines and then taxanes, as monotherapy or concomitantly with trastuzumab, which was then given with total one year.5